Please login to the form below

Not currently logged in
Email:
Password:

Clovis Oncology

This page shows the latest Clovis Oncology news and features for those working in and with pharma, biotech and healthcare.

Merck puts prostate cancer firmly in Keytruda’s sights

Merck puts prostate cancer firmly in Keytruda’s sights

BMS is also trialling Opdivo alongside Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) in prostate cancer, as well as studies of its drug alongside chemotherapy and anti-androgen drugs.

Latest news

  • First-line ovarian approval cements AZ’s Lynparza lead First-line ovarian approval cements AZ’s Lynparza lead

    in oncology as well as the cornerstone of a strategic alliance with Merck &Co/MSD, which co-markets the drug. ... Lynparza is already well in front of its PARP inhibitor rivals, Tesaro’s Zejula (niraparib) and Clovis Oncology’s Rubraca (rucaparib).

  • Analysts lukewarm on GSK’s new cancer acquisition Analysts lukewarm on GSK’s new cancer acquisition

    There are plenty of industry observers suggesting GSK is paying too much for Tesaro as it tries to rebuild its oncology pipeline pretty much from scratch, particularly as it spent $13bn ... leading rival Lynparza (olaparib) and two further entrants –

  • GSK buys cancer firm Tesaro for $5.1bn GSK buys cancer firm Tesaro for $5.1bn

    of the year – gives GSK rights to approved PARP inhibitor Zejula (niraparib), which is jostling for market share with AstraZeneca's Lynparza (olaparib) and Clovis Oncology's Rubraca (rucaparib). ... Following behind are two other immuno-oncology

  • AZ and Clovis PARP inhibitors show their mettle at ESMO AZ and Clovis PARP inhibitors show their mettle at ESMO

    There was good news at the ESMO conference for both AstraZeneca and Clovis Oncology as they push to extend the use of their PARP inhibitors into new cancer patient groups. ... extend its lead over its PARP inhibitor rivals, Tesaro's Zejula (niraparib)

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    New combinations and novel mechanisms on show. The countdown to Europe’s premier oncology conference ESMO has begun, and once again it promises to deliver an astonishing array of new studies ... In breast cancer, Novartis will be presenting its SOLAR-1

More from news
Approximately 5 fully matching, plus 24 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Roche's Julie Warner joins Boyds Roche's Julie Warner joins Boyds

    She has previously held positions at Clovis Oncology UK, Genzyme and Gregory Fryer Associate, and was most recently senior regulatory programme manager at Roche.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

04 A Healthy Ambience
Creating a Lifeline to the New Digital User...
03 Health Services
How Pharma Companies Can Survive the Patent Cliff Through Digital Innovation...
From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...

Infographics